Search Results
Your search for this matches 25286 pages
Showing 7601 - 7650Expert Point of View: Mary-Ellen Taplin, MD
Invited discussant of the VISION trial, Mary-Ellen Taplin, MD, of Dana-Farber Cancer Institute, Boston, commented on the study, noting that she was a co-investigator of the trial. “Patients with metastatic castration-resistant prostate cancer have a number of treatment options. There are 10...
VISION Trial: Novel PSMA-Targeted Radiotherapy Improves Outcomes in Metastatic Prostate Cancer
Lutetium-177–PSMA-617 (LuPSMA)—an investigational radiolabeled small molecule—significantly improved radiographic progression-free survival and overall survival when added to the standard of care compared with the standard of care alone for men with metastatic castration-resistant prostate cancer...
Registry Provides Information on Pediatric Melanoma
Pediatric melanoma is a rare disease, with only around 400 cases diagnosed in the United States every year. To better understand this disease and how best to treat it, St. Jude Children’s Research Hospital scientists created a registry called Molecular Analysis of Childhood MELanocytic Tumors...
Study Investigates Influence of Race on Receipt of Care for Prostate Cancer
Black men most likely to benefit from advanced prostate cancer therapies are 11% less likely to receive them than non-Black men. This happens despite apparent equal opportunities in obtaining health-care services, a new study focused on American veterans has shown. Disparities Exposed Published by...
Evaluation of Two Doses of Imetelstat in Patients With Relapsed or Refractory Myelofibrosis After JAK Inhibitor Treatment
In a phase II trial reported in the Journal of Clinical Oncology, John Mascarenhas, MD, and colleagues found that treatment with the telomerase inhibitor imetelstat at a dose of 9.4 mg/kg produced clinical benefit in patients with relapsed or refractory myelofibrosis after Janus-associated kinase...
Genomic Characteristics of Pediatric Rhabdomyosarcoma Tumors
In an analysis from an international consortium reported in the Journal of Clinical Oncology, Shern et al identified genomic characteristics and associated outcomes in pediatric rhabdomyosarcoma. Among the findings were that MYOD1 and TP53 mutations were associated with poorer outcomes. As stated...
FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Pretreated Patients With Multiple Myeloma
On July 9, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a...
ASCO Releases New Recommendations on Systemic Therapy Dosing for Adults With Obesity and Cancer
ASCO has approved new recommendations for the appropriate dosing of systemic anticancer agents in adults with obesity and cancer.1 The guideline update was based on evidence collected from a systematic review of the literature published between November 1, 2010, and March 27, 2020, regarding dosing ...
Defining Cure in Multiple Myeloma
The past 2 decades have seen so many advances in the treatment of multiple myeloma; in addition, median patient survival has grown from just 3 years in the late 1990s to between 8 and 10 years today,1 with some patients exceeding that prognosis by many years. Although still considered a stubbornly...
Reflections on Evolution of Breast Cancer Care in India Over the Past 4 Decades
India has witnessed a major paradigm shift in the field of breast cancer and its management over the past 4 decades. The discipline of medical oncology has evolved exponentially over this period—a growth that few other scientific disciplines have experienced. Interventions at the individual,...
Conquer Cancer, the ASCO Foundation, Awards More Than $10 Million to Support Cancer Research
Conquer Cancer, the ASCO Foundation, is pleased to announce the recipients of its awards supporting researchers with projects spanning across many areas in cancer care, including immunotherapy, precision medicine, breast cancer, and palliative care. This year, Conquer Cancer is funding the largest...
Being Both a Cancer Provider and a Cancer Survivor Is a Rare Privilege
Perhaps my 35-year career as a surgical oncologist and researcher specializing in soft-tissue sarcomas should have prepared me to recognize the signs of chronic lymphocytic leukemia (CLL) when they first appeared a few days before Christmas in 2016, but it did not. In fact, my symptoms were so...
Expert Point of View: Edward B. Garon, MD, MS
Invited discussant of the BOOSTER trial,1 Edward B. Garon, MD, MS, Professor of Medicine and Director of the Thoracic Oncology Program, David Geffen School of Medicine at the University of California Los Angeles, said the study’s research question is appropriate, since osimertinib was established...
Study Finds Bevacizumab Offers No Boost to Second-Line Osimertinib in EGFR T790M–Mutated Lung Cancer
For the second-line treatment of advanced EGFR T790M–mutated non–small cell lung cancer (NSCLC), the performance of osimertinib alone was not found to be different from that of osimertinib plus bevacizumab in the phase II ETOP 10-16 BOOSTER trial, reported at a European Society for Medical...
Expert Point of View: Melinda Telli, MD
EA1131 study discussant, Melinda Telli, MD, Associate Professor of Medicine at Stanford University, Director of the Breast Cancer Program at the Stanford Cancer Institute, and Associate Director of the Stanford Women’s Cancer Center, commented: “At this point,1 capecitabine remains preferred as...
EA1131 Trial: Platinum Not Equal to Capecitabine for Residual Disease in Triple-Negative Breast Cancer
In patients with triple-negative breast cancer who have residual disease after neoadjuvant chemotherapy, adjuvant capecitabine remains the standard of care. In the multicenter randomized noninferiority EA1131 trial, which included primarily basal tumors, noninferiority of adjuvant platinum over...
Expert Point of View: Nicolas Girard, MD, PhD
Invited discussant Nicolas Girard, MD, PhD, of the Curie Institute, Paris, said, “A major challenge in NSCLC is what happens when osimertinib resistance develops.” “A key takeaway point from this study is that the efficacy is driven by resistance mechanism. The overall response rate was 47% in the ...
Amivantamab/Lazertinib Combination May Overcome Osimertinib Resistance in Patients With EGFR-Positive NSCLC
Combination targeting of epidermal growth factor receptor (EGFR) with amivantamab/lazertinib achieved durable responses in more than one-third of chemotherapy-naive patients with EGFR-mutant non–small cell lung cancer (NSCLC) that had progressed on osimertinib, according to a cohort analysis of the ...
Novel Targeted Agents for the Treatment of Myelofibrosis
“Progress lies not in enhancing what is, but in advancing toward what will be.” –Kahlil Gibran To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting &...
Novel BCL2 Inhibitor Shows Activity in CLL in Phase I Trial
The novel, selective BCL2 inhibitor lisaftoclax (APG-2575) has shown activity in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in a phase I study reported at the 2021 ASCO Annual Meeting.1 Preliminary data suggest that lisaftoclax stands out for its favorable safety...
Expert Point of View: Jacqueline C. Barrientos, MD, MS
Invited discussant Jacqueline C. Barrientos, MD, MS, of Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell in Great Neck, New York, noted that, although both ibrutinib and venetoclax have shown superior results to chemotherapy, each drug is associated with toxicity....
Expert Point of View: Jason J. Luke, MD
Invited discussant of the C-144-01 study,1 Jason J. Luke, MD, Associate Professor of Medicine and Director of the Cancer Immunotherapeutics Center, University of Pittsburgh Hillman Cancer Center, Pittsburgh, noted that lifileucel is “clearly an active regimen in the post–PD-1/CTLA-4 setting and one ...
Early Adopter of Breast Conservation, Surgical Oncologist Augusto Leon, MD, Reflects on Cancer Care in Chile
In this installment of the occasional department on Global Health-Care Equity, Guest Editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Augusto Leon, MD, a surgical oncologist and Head of the Program of Cancer at Pontifical University of Chile, Santiago. Dr. Are is JL & CJ Varner...
Lifileucel After Disease Progression in Metastatic Melanoma: Durable Responses Achieved in Phase II Trial
Despite the fact that we have made significant progress in metastatic melanoma with immune checkpoint inhibitors—now the standard of care—most patients experience disease progression and are left without approved treatments. There is a need for newer treatments with clinical benefit. Lifileucel, an ...
Predicting Global Cancer Trends in 2021
Although we are just halfway through 2021, the outlook for improvements in global cancer trends looks grim. According to new estimates by the International Agency for Research on Cancer’s Global Cancer Observatory, the global cancer burden rose to 19.3 million cases and 10 million deaths in 2020...
ADAPT Trial: ‘Excellent’ Outcomes Reported With Neoadjuvant Dual HER2 Therapy in Breast Cancer
The first overall survival analysis of the WGS-ADAPT HER2+/HR– study, which evaluated neoadjuvant therapy in patients with hormone receptor–negative, HER2-positive disease, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or with the chemotherapy-free regimen of...
Sacituzumab Govitecan-hziy: Welcome Addition to Advanced Urothelial Cancer Treatments, but Time to Figure Out Sequencing and Combinations
The results of Cohort 1 of the phase II trial TROPHY-U-01 (IMMU-132-06; ClinicalTrials.gov identifier NCT03547973), published in the Journal of Clinical Oncology by Tagawa et al and reviewed in this issue of The ASCO Post, led to the recent accelerated U.S. Food and Drug Administration (FDA)...
Sacituzumab Govitecan-hziy in Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy
In a cohort of the phase II TROPHY-U-01 trial reported in the Journal of Clinical Oncology, Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, and colleagues, found that the antibody-drug conjugate sacituzumab govitecan-hziy produced durable responses in patients with metastatic...
Reducing Prostate Cancer Disparity by Bringing Care to Underserved Populations
The dire cancer incidence and mortality statistics for Black patients compared with White patients are well known. Collectively, Black individuals have the highest mortality rate and shortest survival of any racial or ethnic group in the United States for most cancers. Black men also have the...
Enfortumab Vedotin Represents a Community of Work in Antibody-Drug Conjugates Targeting Cancer
The first known clinical trial report of an antibody-drug conjugate was a phase 0/I pharmacodynamic and safety study of a conjugate that targeted carcinoembryonic antigen and delivered a payload of vinca alkaloid in eight patients with ovarian or colorectal cancer.1 This work built on the work of...
Disease Risk Associated With Protein-Truncating and Rare Missense Variants in Breast Cancer Risk Genes
In a study reported in TheNew England Journal of Medicine, Leila Dorling, PhD, of the Centre for Cancer Genetic Epidemiology, Departments of Public Health and Primary Care, University of Cambridge, United Kingdom, and colleagues in the international Breast Cancer Association Consortium (BCAC),...
Caryn Lerman, PhD, Elected President of the AACI
Caryn Lerman, PhD, is the new President of the Association of American Cancer Institutes (AACI). Dr. Lerman is Director of the University of Southern California (USC) Norris Comprehensive Cancer Center in Los Angeles and Associate Dean for Cancer Programs and the H. Leslie and Elaine S. Hoffman...
Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
On May 20, 2021, nivolumab was approved for adjuvant treatment of patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease after neoadjuvant chemoradiotherapy.1,2 Supporting Efficacy Data Approval was based on findings from the...
5- vs 2-Year Course of Zoledronate for Patients With Early Breast Cancer
On this week's episode, we’re discussing the effect of a 5- vs 2-year course of zoledronate for patients with early breast cancer; a recent FDA approval in locally advanced cutaneous squamous cell carcinoma; and a study that examined how reduced time to completion of treatment in patients with...
Enfortumab Vedotin-ejfv Granted Regular Approval in Treatment of Locally Advanced or Metastatic Urothelial Cancer
On July 9, 2021, the U.S. Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev), a Nectin-4–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and...
Study Finds Response to COVID-19 Vaccination Varies Widely in Patients With Multiple Myeloma
Patients with multiple myeloma had a wide variety of responses to COVID-19 vaccines—in some cases, no detectable response at all—pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published by Van Oekelen et al in Cancer Cell. Mount...
Is There a Link Between Use of Antibiotics and Early-Onset Colorectal Cancer?
Study findings presented by Perrott et al at the ESMO World Congress on Gastrointestinal Cancer (Abstract SO-25) showed that the use of antibiotics may be linked to colon tumor formation across all patient age groups, especially in those younger than 50 years. These results raise fresh concerns...
BCMA-Directed CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
In the phase Ib/II CARTITUDE-1 trial reported in The Lancet, Jesus G. Berdeja, MD, and colleagues found that ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy with two B-cell maturation antigen (BCMA)-targeting single-domain antibodies, produced a high rate of...
Annual Report to the Nation: Continued Decline in Cancer Death Rate
Overall cancer death rates continue to decline in men and women for all racial and ethnic groups in the United States, according to the latest Annual Report to the Nation on the Status of Cancer. During 2001 to 2018, declines in lung cancer death rates accelerated, and death rates for melanoma...
Is Chemotherapy Associated With Complications or Poorer Outcomes Among Women Undergoing Immediate Breast Reconstruction?
In a cohort study reported in JAMA Surgery, Hart et al found that treatment with either neoadjuvant or adjuvant chemotherapy was not associated with an increased risk of complications or poorer patient-reported outcomes in women undergoing mastectomy for breast cancer with immediate breast...
Using ctDNA to Measure Molecular Residual Disease in Patients With Colorectal Cancer
A team of investigators in Japan used a personalized assay for circulating tumor DNA (ctDNA) levels in plasma to monitor molecular residual disease following surgery in patients with resectable colorectal cancer. Their subgroup analysis found statistically significant associations between ctDNA...
Molecular Imaging May Improve the Staging and Treatment of Pancreatic Ductal Adenocarcinoma
For patients with pancreatic ductal adenocarcinoma, molecular imaging may improve staging and clinical management of the disease, according to research published by Röhrich et al in The Journal of Nuclear Medicine. In a retrospective study of patients with pancreatic ductal adenocarcinomas, the...
Study Recommends Improvements for Cancer Care at Network Sites
New research published in JNCCN—Journal of the National Comprehensive Cancer Network assessed the quality of cancer care delivered through extended sites coordinated by some of the country’s largest cancer centers. The study was developed to implement strategies for disseminating discoveries and...
Mechanisms of Acquired Resistance to KRAS G12C Inhibition in Patients With Cancer
In a study reported in The New England Journal of Medicine, Awad et al identified potential mechanisms of acquired resistance to the KRAS G12C inhibitor adagrasib in patients receiving the agent for treatment of KRAS G12C–mutant cancers. As noted by the investigators, clinical trials of the KRAS...
New Recommendations From WHO and HRP for the Screening and Treatment of Cervical Cancer
The World Health Organization (WHO) and the Human Reproduction Programme (HRP)—the main instrument within the United Nations system for research in human reproduction—have launched a new guideline to help countries make faster progress, more equitably, in the screening and treatment of cervical...
Study Finds Reduced Treatment Delays for Patients With Breast Cancer May Improve Survival Rates
Research published by Pratt et al in Annals of Surgical Oncology showed an increase in survival rates when treatment options—surgery, chemotherapy, and radiation—are completed within 38 weeks from the time of diagnosis for patients with breast cancer. Optimal Treatment Duration The observational...
Individualized Nutritional Support for Patients With Cancer
Among 506 hospitalized patients with cancer at risk of malnutrition, individualized nutritional support reduced the risk of mortality compared to consumption of standard hospital food. The findings from a preplanned secondary analysis of the prospective, randomized, multicenter EFFORT trial,...
Oncolytic Adenovirus for Malignant Glioma: Feasibility and Safety
In a first-in-human phase I trial reported in The Lancet Oncology, Fares et al found that neural stem cell delivery of an oncolytic adenovirus (NSC-CRAd-S-pk7) was safe and feasible in patients with newly diagnosed malignant glioma, with immunologic and histopathologic findings supporting continued ...
International Esodata Study Group Model for Predicting 90-Day Mortality After Esophagectomy
In a retrospective analysis reported by researchers from the International Esodata Study Group (IESG) in JAMA Surgery, D’Journo et al developed a model for predicting risk of 90-day mortality following esophagectomy for patients with esophageal or gastroesophageal junction cancer. As stated by the...
FDA Approves Expanded Indication for Pembrolizumab in Locally Advanced Cutaneous Squamous Cell Carcinoma
On July 6, the U.S. Food and Drug Administration (FDA) approved an expanded label for pembrolizumab, an anti–PD-1 agent, as monotherapy for patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation. This approval is based on data from the second...
